Abstract
Although aspirin has become an established medicine for cardiac and cerebrovascular diseases, the optimal dose remains unknown. We evaluated the optimal dose of aspirin on platelet activity and endothelial function by administering 11 healthy male volunteers (32 ± 6 years of age) doses of aspirin that were increased in a stepwise manner (0, 81, 162, 330 and 660 mg/day) every 3 days. Platelet activity was assessed as surface P-selectin expression (%) measured by flow cytometry and the platelet aggregation ratio. Endothelial function in the brachial artery was assessed by measuring flow-mediated dilation (FMD) before and after reactive hyperemia. Platelet aggregation and P-selectin expression were significantly and dose-dependently suppressed (81-660 mg), and the FMD ratio tended to increase from 0 to 162 mg, but decreased significantly at 660 mg. In conclusion, although aspirin suppressed platelet activity and even surface P-selectin expression, higher doses worsened endothelial-mediated arterial dilation.
| Original language | English |
|---|---|
| Pages (from-to) | 267-273 |
| Number of pages | 7 |
| Journal | Heart and Vessels |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 1 2011 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Cite this
Effects of various doses of aspirin on platelet activity and endothelial function. / Furuno, Takashi; Yamasaki, Fumiyasu; Yokoyama, Takeshi; Sato, Kyoko; Sato, Takayuki; Doi, Yoshinori; Sugiura, Tetsuro.
In: Heart and Vessels, Vol. 26, No. 3, 01.05.2011, p. 267-273.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of various doses of aspirin on platelet activity and endothelial function
AU - Furuno, Takashi
AU - Yamasaki, Fumiyasu
AU - Yokoyama, Takeshi
AU - Sato, Kyoko
AU - Sato, Takayuki
AU - Doi, Yoshinori
AU - Sugiura, Tetsuro
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Although aspirin has become an established medicine for cardiac and cerebrovascular diseases, the optimal dose remains unknown. We evaluated the optimal dose of aspirin on platelet activity and endothelial function by administering 11 healthy male volunteers (32 ± 6 years of age) doses of aspirin that were increased in a stepwise manner (0, 81, 162, 330 and 660 mg/day) every 3 days. Platelet activity was assessed as surface P-selectin expression (%) measured by flow cytometry and the platelet aggregation ratio. Endothelial function in the brachial artery was assessed by measuring flow-mediated dilation (FMD) before and after reactive hyperemia. Platelet aggregation and P-selectin expression were significantly and dose-dependently suppressed (81-660 mg), and the FMD ratio tended to increase from 0 to 162 mg, but decreased significantly at 660 mg. In conclusion, although aspirin suppressed platelet activity and even surface P-selectin expression, higher doses worsened endothelial-mediated arterial dilation.
AB - Although aspirin has become an established medicine for cardiac and cerebrovascular diseases, the optimal dose remains unknown. We evaluated the optimal dose of aspirin on platelet activity and endothelial function by administering 11 healthy male volunteers (32 ± 6 years of age) doses of aspirin that were increased in a stepwise manner (0, 81, 162, 330 and 660 mg/day) every 3 days. Platelet activity was assessed as surface P-selectin expression (%) measured by flow cytometry and the platelet aggregation ratio. Endothelial function in the brachial artery was assessed by measuring flow-mediated dilation (FMD) before and after reactive hyperemia. Platelet aggregation and P-selectin expression were significantly and dose-dependently suppressed (81-660 mg), and the FMD ratio tended to increase from 0 to 162 mg, but decreased significantly at 660 mg. In conclusion, although aspirin suppressed platelet activity and even surface P-selectin expression, higher doses worsened endothelial-mediated arterial dilation.
UR - http://www.scopus.com/inward/record.url?scp=79959760348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959760348&partnerID=8YFLogxK
U2 - 10.1007/s00380-010-0054-8
DO - 10.1007/s00380-010-0054-8
M3 - Article
C2 - 21063876
AN - SCOPUS:79959760348
VL - 26
SP - 267
EP - 273
JO - Heart and Vessels
JF - Heart and Vessels
SN - 0910-8327
IS - 3
ER -